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We investigated the effect of budesonide and nedocromil sodium on the secretion of IL-6 and IL-8 by cultured
epithelial cells from healthy nasal mucosa and nasal polyps. Human epithelial cell conditioned media was generated
with fetal calf serum (FCS) in the presence or absence of budesonide and/or nedocromil sodium. Budesonide
inhibited FCS-induced IL-6 and IL-8 release in a dose- dependent manner. The IC25 (25% inhibitory
concentration) of budesonide on IL-6 release was higher in nasal polyp than in nasal mucosa epithelial cells
(34 nM vs. 200 pM). The IC25 of budesonide on IL-8 release was higher in nasal mucosa than in nasal polyps (145 pM
vs. 4 pM). Nedocromil sodium caused a dose-related inhibitory effect on IL-8 release from nasal mucosa (IC25,
207 nM), while it only had a significant effect in nasal polyps at 1075 M. Nedocromil sodium had no effect on IL-6
release. The inhibitory effect of budesonide was higher than that of nedocromil sodium on both nasal polyps and
nasal mucosa. Budesonide and nedocromil sodium may exert their anti-inflammatory action in the respiratory
mucosa by modulating the secretion of IL-6 and IL-8. The different effect of budesonide and nedocromil sodium on
IL-6 and IL-8 release may be explained by differences in the mechanisms which regulate the upregulation of these
cytokines in inflammatory responses.
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Airway epithelial cells express and synthesize a large variety
of mediators which influence the growth, differentiation,
proliferation and activation of inflammatory cells which
contribute to the development of airway inflammation (1).
The introduction of topically administered glucocorticoids
has improved the treatment of airway inflammatory
diseases such as rhinitis, nasal polyps and bronchial asthma
(2). It has been shown that glucocorticoids decrease the
inflammatory infiltration of the respiratory mucosa (3).
This anti-inflammatory effect of glucocorticoids may result,
at least in part, from an inhibition of epithelial cell derived
cytokines. Several in-vitro and in-vivo studies have shownReceived 29 June 2000 and accepted in revised form 14 February
2001.
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0954-6111/01/050408+07 $35?00/0that glucocorticoids may downregulate the secretion of
granulocyte-macrophage colony stimulating factor (GM-
CSF), IL-1b, IL-6, TNFa and IL-8 from epithelial cells.
However, there may be marked differences in the response
of different cytokines to the inhibitory action of glucocor-
ticoids (4–9).
Nedocromil sodium has been widely used in the
treatment of bronchial asthma (10). Nedocromil sodium
inhibits the in-vitro activation of various cell types involved
in airway inflammation, especially neutrophils and eosino-
phils (11). Furthermore, nedocromil sodium decreases the
number and activation of eosinophils in bronchial biopsies
from asthmatic patients (12) and decreases in-vitro eosino-
phil chemotaxis induced by bronchial epithelial cells in-vitro
(13). These effects of nedocromil sodium may also
result from an inhibition of epithelial cell-derived cytokines.
It has been shown that nedocromil sodium inhibits IL-1
and ozone-induced release of IL-8 and GM-CSF from
cultured human bronchial epithelial cells (14–16). We have
previously demonstrated that nedocromil sodium inhibits
GM-CSF release from cultured nasal epithelial cells (5).# 2001 HARCOURT PUBLISHERS LTD
EFFECT OF BUDESONIDE AND NEDOCROMIL SODIUM ON IL-6 AND IL-8 RELEASE 409In this study, we investigate and compare the effect and
potency of budesonide and nedocromil sodium in IL-8 and
IL-6 release from both healthy (nasal mucosa) and inflamed
(nasal polyposis) respiratory tissue.
Material and methods
MATERIALS
Ham’s F-12 medium was provided by Biochorm KG
(Berlin, Germany). Trypan blue, HEPES buffer, penicil-
lin–streptomycin, fetal calf serum and RPMI 1640 were
obtained from Flow Laboratories (Irvin, U.K.), and 24-well
tissue culture clusters were purchased from Costar
(Cambridge, MA, U.S.A.). Amphotericin B was provided
by Squibb (Esplugues de Llobregat, Spain). Budesonide
was obtained from Astra-Espan˜a (Barcelona, Spain) and
nedocromil sodium from Fisons Ibe´rica (Zaragoza, Spain).
Hydrocortisone, human transferrin, bovine insulin, 3,3’,5-
triiode-L-tyrosine sodium salt, glutamine, protease type
XIV were purchased from Sigma Co. (St Louis, MO,
U.S.A.). Endothelial cell growth supplement, epidermal
growth factor, and rat tail collagen type I were obtained
from Collaborative Research Incorporated (Bedford,
U.S.A.). Cytokine ELISA kits were acquired from Amer-
sham Ibe´rica (Madrid, Spain).
SUBJECTS
Nasal mucosa specimens were obtained from 17 subjects
(12 men, five women) aged 28+12 years (range 13–61
years), undergoing nasal corrective surgery for septal
dismorphy, turbinate hypertrophy or both. Skin prick test
for common allergens was positive in two patients. One
patient suffered from allergic rhinitis, another from
vasomotor rhinitis, and another from allergic asthma.
Two patients were on regular treatment with topical
glucocorticoids. Nasal polyp specimens were obtained from
17 patients (10 men, seven women) aged 45+15 years
(range 12–68 years), undergoing nasal polypectomy. The
skin prick test for common allergens was positive in three
patients. Four patients suffered from bronchial asthma
(three of them were allergic) and two were aspirin-
intolerant. Eleven patients received treatment with oral
and/or inhaled glucocorticoids.
EPITHELIAL CELL CULTURE
Tissue specimens were placed in Ham’s F-12 medium
supplemented with penicillin (100 IUml71), streptomycin
(100mgml71), amphotericin B (2 mgml71) and immediately
transported to the laboratory. Isolation of epithelial cells
from healthy nasal mucosas or polyps and epithelial cell
cultures were carried out according to the method we have
previously described (17). Briefly, epithelial cells were
isolated by protease digestion and plated in collagen-coated
wells with 2ml of serum-free Ham’s F-12 medium
supplemented with antibiotics, glutamine and growthfactors, and incubated at 5% CO2 and 378C. Culture
media were changed every 2 days until cell culture
confluence was reached after 7–10 days. Characterization
of epithelial cells was carried out by May–Gru¨nwald–
Giemsa stain and immunocytochemistry using a mono-
clonal antibody (CK 1) to cytokeratin.
GENERATION OF HUMAN EPITHELIAL-
CONDITIONED MEDIA (HECM)
After reaching confluence, HECM was generated as
previously described (17). As we have shown in previous
studies (18) that non-stimulated epithelial cells produce
IL-6 and IL-8, fetal calf serum (FCS) at 10% was used to
increase the secretion of these cytokines. In order to avoid
different effects from FCS from different batches or sources,
the same FCS batch was used in all the experiments.
Cultured epithelial cells were incubated for 48 h with RPMI
1640 medium supplemented with 10% FCS, in the presence
or absence of budesonide (10713 M–1075 M), and/or nedo-
cromil sodium (1078 M–1075 M). HECM were harvested,
centrifuged at 400 g (10min, room temperature), sterilized
through 0?22 mm filters (Millipore) and stored at 7708C
until used. Nedocromil sodium was diluted in culture
medium (RPMI) while budesonide was diluted in dimethyl-
sulphoxide (DMSO). The final concentration of DMSO
(0?1%) had no effect on FCS-induced IL-6 and IL-8 release.
Since nedocromil sodium and budesonide did not reach
50% inhibition of FCS induced IL-6 and IL-8 release in the
majority of experiments, their inhibitory potency was




The concentrations of IL-6 and IL-8 in HECM were
measured by commercial ELISA kits. The limits of
detection were 94 pgml71 for IL-8, and 3 pgml71 for IL-6.
STATISTICAL ANALYSIS
All the results are expressed as mean+SEM. Statistical
evaluation was performed on a Power Macintosh 6100/60
(Apple Computer, Cupertino, CA, U.S.A.) using the
statistical software package Statview II (Brainpower Inc,
Calabasas, CA, U.S.A.). A non-parametric (Wilcoxon
signed rank) test was used for statistical comparison. A
P-value 50?05 was considered statistically significant.
Results
EFFECTS OF FCS ON IL-6 AND IL-8
RELEASE
We investigated the effect of FCS on the release of IL-6 and
IL-8 from cultured nasal epithelial cells through dose-
410 A. XAUBET ET AL.response (0, 0?5, 1, 2?5, 5 and 10%) and time course (6, 12,
24, and 48 h) experiments. FCS increased the release of
both IL-6 (Fig. 1) and IL-8 (Fig. 2) in a dose-related
manner, the maximum effect being at 48 h using 10% FCS.
The effect of 10% FCS after 48 h was used as a positive
control for further experiments.
EFFECTS OF BUDESONIDE AND
NEDOCROMIL SODIUM ON CYTOKINE
RELEASE
Budesonide inhibited FCS-induced IL-6 release from both
nasal mucosa and nasal polyp epithelial cells in a dose-
related fashion. The maximum effect was observed at the
concentration of 1077 M for both nasal mucosa and nasal
polyps (42% and 49% of inhibition, respectively) (Fig. 3).
In contrast, nedocromil sodium had no effect on IL-6
release from both nasal mucosa and nasal polyp epithelialFIG. 1. Release of IL-6 from cultured nasal mucosa
epithelial cells in response to fetal calf serum (FCS). (a)
Time course of IL-6 release. FCS 10% (*) induced a
significant release of IL-6 compared to media-treated
control cells (*) from 6–48 h (n=3). (b) Dose response of
IL-6 release induced by increasing concentrations of FCS
(0?5–10%) over 48 h of incubation (n=3) (*P50?05).cells, even at concentrations such as 1075 M (data not
shown).
The release of IL-8 from cultured nasal mucosa epithelial
cells was inhibited up to 51% by budesonide at 1075 M. In
experiments using nasal polyp epithelial cells, budesonide
caused a dose-related inhibition of IL-8 release, the
maximum effect being at the concentration of 1077 M
(67%) (Fig. 4). Nedocromil sodium inhibited IL-8
release from nasal mucosa epithelial cells in a dose
response fashion (up to 42% at 1075 M). In nasal polyp
epithelial cells, nedocromil sodium only had an inhibitory
effect at 1075 M (38% inhibition) (Fig. 5). The inhibitory
effect of nedocromil sodium (1075 M) plus budesonide
(1077 M–10711 M) on IL-6 and IL-8 release was not
significantly different when compared to that of budesonide
alone (data not shown). No differences were found in the
IL-6 and IL-8 secretions between the experiments using
polyp tissue from patients pretreated or not with gluco-
corticoids.FIG. 2. Release of IL-8 from cultured nasal mucosa
epithelial cells in response to fetal calf serum (FCS). (a)
Time course of IL-8 release. FCS 10% (*) induced a
significant release of IL-8 compared to media-treated
control cells (*) from 6–48 h (n=5). (b) Dose response of
IL-8 release induced by increasing concentrations of FCS
(0?5–10%) over 48 h of incubation (n=6) (*P50?05).
FIG. 3. Effect of budesonide on IL-6 release. Fetal calf
serum (FCS) at 10% increased IL-6 release from both (a)
healthy nasal mucosa and (b) nasal polyp epithelial cells
compared to media-treated cells (C) (*P50?05).
Budesonide (BUD) caused a dose-related inhibitory effect
on FCS-induced IL-6 release from both normal nasal
(n=7) and polyp (n=7) epithelial cells ({P50?05).
FIG. 4. Effect of budesonide on IL-8 release. Fetal calf
serum (FCS) at 10% increased IL-8 release from both (a)
healthy nasal mucosa and (b) nasal polyp epithelial cells
compared to media-treated cells (C) (*P50?05).
Budesonide (BUD) caused an inhibitory effect on FCS-
induced IL-8 on both normal nasal (n=6) and polyp
(n=6) epithelial cells ({P50?05).
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NEDOCROMIL SODIUM INHIBITORY
POTENCY ON IL-8 AND IL-6 RELEASE
(TABLE 1)
The IC25 of budesonide on FCS induced IL-6 release
was higher in nasal polyps (34 nM) than in nasal mucosa
(200 pM) epithelial cells. In contrast, the IC25 of
budesonide on FCS induced IL-8 release was higher in
nasal mucosa epithelial cells in comparison with nasal
polyps (145 pM vs. 4 pM). The IC25 of nedocromil sodium on
IL-8 release was higher in nasal mucosa than in
nasal polyps (207 nM vs. 2mM). The IC25 of nedocromil
sodium on IL-6 release from both nasal polyps and
nasal mucosa was considered higher than 10mM.
The inhibitory effect of budesonide was higher than that
of nedocromil sodium in both nasal polyps and nasal
mucosa.Discussion
In the present study we report that budesonide inhibits IL-6
and IL-8 release from both nasal mucosa and nasal polyp
epithelial cells, while nedocromil sodium only had an effect
on IL-8 release. Our results suggest that topical anti-
inflammatory drugs may decrease airway inflammation by
blocking the effects of these mediators produced by
epithelial cells.
IL-6 and IL-8 are multi-functional cytokines which
participate in inflammatory and immune responses. IL-6
increases the production of immunoglobulins by B-lym-
phocytes, stimulates the activation and proliferation of T-
lymphocytes and induces the production of acute phase
proteins (19). IL-8 is a potent chemotactic factor for
neutrophils and eosinophils in vitro (20,21). Several studies
have shown the role of these cytokines in the regulation of
airway inflammation. Human bronchial and nasal epithelial
cells as well as immortalized epithelial cell lines may
FIG. 5. Effect of nedocromil sodium (NS) on IL-8 release.
Fetal calf serum (FCS) at 10% increased IL-8 release from
both (a) healthy nasal mucosa and (b) nasal polyp
epithelial cells compared to media-treated cells (C)
(*P50?05). NS inhibited FCS-induced IL-8 release from
healthy nasal mucosa in a dose-response fashion (n=7).
In nasal polyp epithelial cells, NS only showed an
inhibitory effect at 1075 M (n=6) ({P50?05).
TABLE 1. Inhibitory concentration of 25% (IC25) of
budesonide and nedocromil sodium on interleukin-6 (IL-
6) and interleukin-8 (IL-8) release induced by 10% FCS
from nasal mucosa and nasal polyp epithelial cells
IC25
Cytokines Nasal mucosa Nasal polyps
Budesonide
IL-6 200 pM 34 nM
IL-8 145 pM 4pM
Nedocromil sodium
IL-6 410mM 410mM
IL-8 207 nM 2mM
412 A. XAUBET ET AL.generate IL-6 and IL-8 in basal conditions, and under the
influence of a variety of stimuli, such as TNFa, syncytal
respiratory virus, LPS, endothelin-1 and vasoactive intest-
inal peptide (22–26). We selected IL-6 and IL-8 because we
have previously demonstrated that these cytokines, together
with GM-CSF, are the main cytokines released in-vitro by
human nasal mucosa and polyp epithelial cells (18). On the
other hand, we have reported that eosinophil survival
induced by epithelial cell secretions from nasal polyps is
partially blocked by antibodies to IL-8 (18). Other
cytokines which may influence the migration of eosinophils
to nasal polyps include IL-5, RANTES and eotaxin.
Although IL-5 may be upregulated in nasal polyps (27),
we have not found this cytokine expressed in nasal polyp
epithelial cells. On the other hand, the secretion of
RANTES has been found to be small (4,28).
Recent in-vitro studies have suggested that some cyto-
kines may be resistent to the abrogating effect of
glucocorticoids. Linden et al. (29) reported that in alveolar
macrophages and peripheral blood monocytes, the inhibi-
tory effect of budesonide is stronger on GM-CSF than on
IL-1 or IL-6 secretion. Moreover, Strieter et al. (30)
demonstrated that the production of TNFa by alveolar
macrophages was more refractory to corticosteroids than
blood monocytes. In experiments using BEAS 2B cells,
Levine et al. (6) showed that dexamethasone abrogated the
secretion of IL-6 induced by TNFa, whereas this corticos-
teroid only had a weak inhibitory effect on IL-8 release. In
contrast, Kwon et al. (8) showed that dexamethasone
inhibited tumour necrosis factor-induced IL-8 expression
and secretion from both cultured human airway epithelial
cells and A549 epithelial cells. It has also been reported that
dexamethasone does not inhibit elastase-induced IL-8
release from a cystic fibrosis nasal epithelial cell line (31).
The results of our study show that budesonide inhibits IL-6
and IL-8 release from both nasal mucosa and nasal polyps
epithelial cells. However, the inhibitory potency of bude-
sonide on IL-6 was higher in nasal mucosa epithelial cells
than in nasal polyps. In contrast, the effect on IL-8 release
was more marked in nasal polyp epithelial cells than in
nasal mucosa epithelial cells. These marked differences in
the responses of cells and cytokines to the inhibitory action
of glucocorticoids may depend, in part, on both the cell
type and the mechanisms of the inhibitory process.
Glucocorticoid effects are mediated by the direct binding
of the glucocorticoid receptor complex to glucocorticoid
responsive elements in the promoter region of cytokine
genes, as well as by an interaction of these complexes with
pro-inflammatory transcription factors such as activating-
protein-1 (AP-1) or nuclear factor-kappa B (NFkB). Other
mechanisms may include the reduction of cytokine mRNA
half-life through post-transcriptional interactions and up-
regulation of the expression of cytokine inhibitory proteins
which deactivate transcription factors (32). It has been
shown that glucocorticoid-mediated inhibition of IL-6
expression in epithelial BEAS-2B cells involves both
transcriptional and post-transcriptional mechanisms (6).
On the other hand, the inhibition of transcription factors
appears to be involved in the decrease of IL-8 production in
human cultured bronchial epithelial cells (33).
EFFECT OF BUDESONIDE AND NEDOCROMIL SODIUM ON IL-6 AND IL-8 RELEASE 413Nasal polyps are characterized by an inflammatory
process of the nasal respiratory mucosa and represent a
good model of inflamed respiratory tissue (34). One
possible mechanism whereby eosinophil infiltration occurs
in nasal polyps is the secretion of cytokines, such as IL-5,
IL-8 and GM-CSF, which prolongs eosinophil survival,
and the local production of these mediators is a potential
target for therapeutic intervention (4,17,18,34–36). In
addition, it has been reported that in cystic fibrosis, a
disease with a high prevalence of nasal polyps, respiratory
epithelial cells show an excessive secretion of IL-8 (35,37).
All these findings and the results of our study support the
usefulness of topical glucocorticoids in the treatment of
nasal polyposis.
We have also found that nedocromil sodium inhibited
IL-8 release from epithelial cells. This finding is in keeping
with the potential ecacy of nedocromil sodium in the
treatment of non-allergic obstructive lung diseases. De Jong
et al. and Schoonbrood et al. showed that the number of
exacerbations of the disease was fewer during treatment
with this drug (38,39). Airway infiltration by neutrophils is
the main histological characteristic of chronic obstructive
pulmonary disease (COPD) (40), and high concentrations
of IL-8 and neutrophils have been found in bronchoalveo-
lar lavage from COPD patients (41). This finding suggests
that IL-8 is one of the chemotactic factors reponsible for
the accumulation of increased numbers of neutrophils in
the airways of patients with COPD. The inhibitory effect of
nedocromil sodium on IL-8 observed in our study suggests
that this drug could decrease the neutrophilic inflammation
of respiratory mucosa and explain, in part, their ecacy in
the treatment of these patients.
The extrapolation of the present in-vitro results to the
clinical setting have to take in account the concentrations of
drugs used in the experiments. Our results may be of clinical
relevance since it has been demonstrated that the inhalation
of 500 mg of budesonide results in a blood plasma
concentration of 1079 M (42) and we have observed that
this concentration is able to inhibit cytokine release. In
conclusion, our findings indicate that topical anti-inflam-
matory drugs may exert part of their therapeutic effect on
inflammatory airway diseases by modulating the release of
IL-6 and IL-8 from epithelial cells. Moreover, the different
effects of budesonide and nedocromil sodium on IL-6 and
IL-8 release may be explained by differences in the
mechanisms which regulate the upregulation of these
cytokines in inflammatory responses.
Acknowledgements
This work was supported by SEPAR, FUCAP, FIS 95/0248
and CIRIT 1998 SGR 112.
References
1. Levine SJ. Bronchial epithelial cell-cytokine interac-
tions in airway epithelium. J Invest Med 1995; 43:
241–249.2. Brattsand R, Selroos O. Current drugs for respiratory
diseases: glucocorticoids. In: Metzger WJ, ed. Drugs
and the Lung. New York: Rave Press, 1994; 101–120.
3. Trigg C, Manolitsas ND, Wang J, et al. Placebo-
controlled immunopathology study of four months of
inhaled corticosteroids in asthma. Am J Respir Crit
Care Med 1994; 150: 17–22.
4. Mullol J, Lo´pez E, Roca-Ferrer J, et al. Effects of
topical anti-inflammatory drugs on eosinophil survival
primed by epithelial cells. Additive effect of glucocorti-
coids and nedocromil sodium. Clin Exp Allergy 1997;
27: 1432–1441.
5. Roca-Ferrer J, Mullol J, Lo´pez E, et al. Effect of
topical anti-inflammatory drugs on epithelial cell-
induced eosinophil survival and GM-CSF secretion.
Eur Respir J 1997; 10: 1489–1495.
6. Levine SJ, Larive´e P, Logun C, Angus CW, Shelhamer
JH. Corticosteroids differentialy regulate secretion of
IL-6, IL-8 and G-CSF by a human bronchial epithelial
cell line. Am J Physiol 1993; 265: L360–L368.
7. Adkins KK, Levan TC, Miesfeld RL, Bloom JW.
Glucocorticoid regulation of GM-CSF. Evidence for
transcriptional mechanisms in airway epithelial cells.
Am J Physiol 1998; 275: L372–L378.
8. Kwon OJ, Au BT, Collins PD, et al. Tumor necrosis
factor induced interleukin-8 expression in cultured
airway epithelial cells. Am J Physiol 1994; 267:
L398–L405.
9. Sousa AR, Poston RN, Lane SJ, Narhosteen JA, Lee
TH. Detection of GM-CSF in asthmatic bronchial
epithelium and decrease by inhaled corticosteroids. Am
Rev Respir Dis 1993; 147: 1557–1561.
10. de Jong JW, Postma DS, de Monchy JGR, Koe´ter GH.
A review of nedocromil sodium in asthma therapy. Eur
Respir Rev 1993; 3: 511–519.
11. Bruijnzeel PLB, Warringa RAJ, Kok PTM, Kreukniet
J. Inhibition of neutrophil and eosinophil induced
chemotaxis by nedocromil sodium and sodium cromo-
glycate. Br J Pharmacol 1990; 99: 798–802.
12. Manolitsas ND, Wang J, Devalia JL, Trigg CJ,
McAulay AE, Davies RJ. Regular albuterol, nedocro-
mil sodium, and bronchial inflammation in asthma. Am
J Respir Crit Care Med 1995; 151: 1925–1930.
13. Abdelaziz MM, Devalia JL, Khair OA, et al. The effect
of nedocromil sodium on human airway epithelial cell-
induced eosinophil chemotaxis and adherence to hu-
man endothelial cell in vitro. Eur Respir J 1997; 10:
851–857.
14. Marini M, Soloperto M, Zheng Y, Mezzeti M, Mattoli
S. Protective effect of nedocromil sodium on the IL-1
induced release of GM-CSF from cultured human
bronchial epithelial cells. Pulm Pharmacol 1992; 5:
61–65.
15. Vittori E, Sciacca F, Colotta F, Mantovani A, Mattoli
S. Protective effect of nedocromil sodium on the
interleukin-1 induced production of interleukin-8 in
human bronchial epithelial cells. J Allergy Clin
Immunol 1992; 90: 76–84.
16. Rusznak C, Devalia JL, Sapsford RJ, Dvies RJ. Ozone-
induced mediator release from human bronchial
414 A. XAUBET ET AL.epithelial cells in vitro and the influence of nedocromil
sodium. Eur Respir J 1996; 9: 2298–2305.
17. Xaubet A, Mullol J, Lo´pez E, et al. Comparison of the
role of nasal polyp and normal nasal mucosal epithelial
cells on in vitro eosinophil survival. Mediaton by GM-
CSF and inhibition by dexamethasone. Clin Exp
Allergy 1994; 24: 307–317.
18. Mullol J, Xaubet A, Gaya A, et al. Cytokine gene
expression and release from epithelial cells. A compar-
ison study between healthy nasal mucosa and nasal
polyps. Clin Exp Allergy 1995; 25: 607–615.
19. Zitnik RJ, Elias JA. Interleukin-6 and the lung. In:
Kelly J, ed. Cytokines of the Lung. New York: Marcel
Dekker, 1993; 229–280.
20. Baggiloloni M, Dewald B, Moser B. Interleukin-8 and
related chemotactic cytokines-CXC and CC chemo-
kines. Adv Immunol 1994; 55: 97–179.
21. Erger RA, Casale TB. Interleukin-8 is a potent
mediator of eosinophil chemotaxis through endothe-
lium and epithelium. Am J Physiol 1995; 268:
L117–L122.
22. Marini M, Vittori F, Hollemborg J, Mattoli S.
Expression of the potent inflammatory cytokines,
granulocyte-macrophage colony stimulating factor
and interleukin-6 and interleukin-8, in bronchial
epithelial cells of patients with asthma. J Allergy Clin
Immunol 1992; 89: 1001–1009.
23. Mullol J, Baraniuk JN, Logun C, Benfield T, Picado C,
Shelhamer JH. Endothelin-1 induces GM-CSF, IL-6,
and IL-8 but not G-CSF release from a human
bronchial epithelial cell line (BEAS 2B). Neuropeptides
1996; 30: 551–556.
24. Mullol J, Baraniuk JN, Pitale MC, et al. Vasoactive
intestinal peptide (VIP) induces IL-6, and IL-8 but
not G-CSF and GM-CSF release from a human
bronchial epithelial cell line. Neuropeptides 1997; 31:
119–124.
25. Black HR, Yankaskas JR, Johnson LG, Noah TL.
Interleukin-8 production by cystic fibrosis nasal epithe-
lial cells after tumor necrosis factor-a and respiratory
syncital virus stimulation. Am J Respir Cell Mol Biol
1998; 19: 210–215.
26. Khair OA, Devalia JL, Abdelaziz MM, Sapsford RJ,
Tarraf H, Davies RJ. Effect of Haemophilus influenzae
endotoxin on the synthesis of IL-6, IL-8, TNF-a,
and the expression of ICAM-1 in cultured human
bronchial epithelial cells. Eur Respir J 1994; 7:
2109–2116.
27. Bachert C, Wagenman M, Hauser U, Rudack C. IL-5
synthesis is upregulated in human nasal polyp tissue. J
Allergy Clin Immunol 1997; 99: 837–842.
28. Abdelaziz MM, Devalia JL, Khair OA, Bayram H,
Prior AJ, Davies RJ. Effect of fexofenadine on
eosinophil-induced changes in epithelial permeability
and cytokine release from nasal epithelial cells of
patients with seasonal allergic rhinitis. J Allergy Clin
Immunol 1998; 101: 410–420.
29. Linden M, Brattsand R. Effects of a corticosteroid,
budesonide, on alveolar macrophages and bloodmonocyte secretion of cytokines: differential sensitivity
of GM-CSF, IL-1b, and IL-6. Pulm Pharmacol 1994; 7:
43–47.
30. Strieter RM, Remick DG, Lynch III JP, et al.
Differential regulation of tumor necrosis factor-a in
human alveolar macrophages and peripheral blood
monocytes: a cellular and molecular analysis. Am J
Respir Cell Mol Biol 1989; 1: 57–63.
31. Be´dard M, McClure CD, Schiller NL, Francoeur C,
Cantin C, Denis M. Release of interleukin-8, inter-
leukin-6, and colony stimulating factors by upper
airway epithelial cells: implications for cystic fibrosis.
Am J Respir Cell Mol Biol 1993; 9: 455–462.
32. Brattsand R, Linden M. Cytokine modulation by
glucocorticoids: mechanisms and actions in cellular
studies. Alim Pharmacol Ther 1996; 10 (Suppl. 2):
81–90.
33. Mukaida N, Morita M, Ishikawa Y, et al. Novel
mechanism of glucocorticoid-mediated gene repression.
J Biol Chem 1994; 269: 13289–13295.
34. Jordana M, Dolovich J, Ohno I, Finotto S, Denburg J.
Nasal polyposis: a model for chronic inflammation. In:
Busse WW, Holgate ST, eds. Asthma and Rhinitis.
Boston: Blackwell Scientific Publications, 1995; 156–
165.
35. Brihaye P, Jorissen M, Clement PA. Chronic rhinosi-
nusitis in cystic fibrosis (mucoviscidosis). Acta Otorhi-
nolaryngol Belg 1997; 51: 323–337.
36. Allen JS, Eisma R, Leonard G, Lafreniere D,
Kreutzer D. Interleukin-8 expression in human nasal
polyps. Otolaryngol Head Neck Surg 1997; 117:
535–541.
37. Bonfield TL, Konstan MW, Berger M. Altered
respiratory epithelial cell cytokine production in
cystic fibrosis. J Allergy Clin Immunol 1999; 104:
72–78.
38. de Jong JW, Postma DS, van der Mark TW,
Koe¨ter GH. Effects of nedocromil in the treat-
ment of non-allergic subjects with chronic obstruc-
tive pulmonary disease. Thorax 1994; 49:
1022–1024.
39. Schoonbrood DFM, Out TA, Hart AAM, Habets
FJM, Roos CM, Jansen HM. Nedocromil sodium in
obstructive airway disease: effect on symptoms and
plasma protein leakage in sputum. Eur Respir J 1997;
10: 1500–1506.
40. Ollerenshaw SL, Woollcock AJ. Characteristics of the
inflammation in biopsies from large airways of subjects
with chronic airflow limitation. Am Rev Respir Dis
1992: 145: 922–927.
41. Pesci A, Balbi B, Majori M, Cacciani G, Bertacco S,
Alciato P, Donner CF. Inflammatory cells and
mediators in bronchial lavage of patients with chronic
obstructive pulmonary disease. Eur Respir J 1998; 12:
380–386.
42. Ryrfeldt A, Andersson P, Edsbacker S, To¨nnesson M,
Davies D, Pauwels R. Pharmacokinetics and metabo-
lism of budesonide, a selective glucocorticoid. Eur J
Respir Dis 1982; 122 (Suppl.): 86–95.
